

**Martin A. Hay & Co.**

13 Queen Victoria Street  
Macclesfield  
Cheshire SK11 6LP  
UNITED KINGDOM

Tel: (+44) 1625 500057  
Fax: (+44) 1625 500058

E-mail: martinahay@martin-a-hay.com

**FACSIMILE TRANSMITTAL SHEET**

**Date:** 4th June 2003

**Total Number of Pages:** 15  
(including cover page)

**To:** Commissioner for Patents  
USPTO

**FAX RECEIVED**

JUN 05 2003

**FAX Number:** 001 703 308 4556

**GROUP 1600**

**From:** Martin A Hay

**FAX Number:** (44) 1625 500058

**OFFICIAL**

**Acknowledgment Requested:**

**Yes**

**No**


**Message:**

**Re:** Applicant: Liebeschuetz et al  
US Appln Serial No. 1-/030,187  
Our Ref: 00219/US

**NOTE:**

This facsimile is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you have received this facsimile in error, please telephone (44) 1625 500057 collect.

#8  
6/6/03  
C. Style

CERTIFICATION OF FACSIMILE TRANSMISSION	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
<u>MARTIN A HAY</u> Type or print name of person signing certification	
 Signature	<u>June 4, 2003</u> Date

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : LIEBESCHUETZ, John Walter  
MURRAY, Christopher William  
YOUNG, Stephen Clinton  
CAMP, Nicholas Paul  
JONES, Stuart Donald  
WYLIE, William Alexander  
MASTERS, John Joseph  
WILEY, Michael Robert  
SHEEHAN, Scott Martin  
ENGEL, David Birenbaum  
WATSON, Brian Morgan  
GUZZO, Peter Robert  
MAYER, Michael John

Serial No. : 10/030,187 )  
Filed : 04 February 2002 ) Group Art Unit:  
For : Serine Protease Inhibitors ) 1624  
Docket No. : 00219/US ) Examiner:  
HABTE, KAHSAI

06/06/2003 PSTANBAC 00000009 501230 10030187

01 FC:1460 130.00 CH

Serial No. 10/030,187

RESPONSE AND AMENDMENT

Commissioner for Patents  
US Patent & Trademark Office  
2011 South Clark Place  
Customer Window  
Crystal Plaza Two, Lobby, Room 1B03  
UNITED STATES

Sir:

This communication is being filed in response to the Office Communication dated May 7, 2003, Paper Number 5.

AMENDMENT

Please cancel Claims 1-16, 19-27, 30 and 33. Only Claims 34-36 will then remain in the application.

Applicants reserve the right to pursue claims to all of the subject matter in this application.

REMARKS

Applicants have restricted the application to the subject matter of Claims 34 to 36. Claim 34 is directed to the compound of Example 48 and its physiologically acceptable salts. Claim 35 is directed to a pharmaceutical composition comprising this compound. Claim 36 is directed to a method of using this compound as an antithrombotic agent.

AMENDMENT OF INVENTORSHIP UNDER 37 C.F.R. 1.48(b)

Following the cancellation of Claims 1-16, 19-27, 30 and 33, the inventorship needs to be corrected. WILEY, Michael Robert is the sole inventor of the subject matter of Claims 34 to 36.

An amendment of the inventorship is attached.

Serial No. 10/030,187

**ELECTION/RESTRICTION**

The Examiner has requested that the claims be restricted to the invention of one of nine groups, identified as Groups I to IX in the Office Communication.

In response, Applicants have voluntarily restricted the application to the species of Claims 34 to 36, reserving the right to pursue claims to all of the subject matter of the application in a continuation application.

Since Applicant has voluntarily restricted the application to a single species, it is respectfully submitted that the requirement to restrict the application in the manner requested by the Examiner has been rendered moot. Applicants have not acquiesced with the Examiner's groupings of the inventions in this application and reserve the right to traverse any restriction of the claims in any continuation application to be filed off this application.

**INFORMATION DISCLOSURE STATEMENT**

As a means of complying with the duty of disclosure, Applicant's submit an "Information Disclosure Statement by Applicant" on PTO Form PTO/SB/08A for consideration by the Examiner. Since this statement is being submitted during the period specified in 37 C.F.R. § 1.97(b), it is believed that no fee is due for this submission. However, should an Office Action on the merits have been mailed, please charge Deposit Account No. 50-1230 in the amount of the fee under 37 C.F.R. § 1.17(p), and consider the information under 37 C.F.R. § 1.97(c).

It is understood that the Examiner has received a

Serial No. 10/030,187

copy of the International Search Report and copies of the documents cited therein (documents B1, B3 and B4). If this is incorrect, the Examiner is kindly requested to contact the undersigned to request copies.

Applicants would also like to provide the Examiner the following background information:

#### BACKGROUND INFORMATION

This application has been restricted, voluntarily, to the compound of Claim 34. This compound is exemplified in Example 48.

The compound of Example 48 was first disclosed in Example 318 of PCT/GB00/02302, from which the present application claims priority under 35 U.S.C. § 119.

PCT/GB00/02302 has entered the U.S. national stage as U.S. patent application serial number 09/926,712. The claims in the 09/926,712 application have been amended so as not to read on any of the compounds originally claimed in the present application.

The compound was invented in the course of a research collaboration between Eli Lilly and Company (the assignee of record) and Protherics Molecular Design Limited (now Tularik Limited, a subsidiary of Tularik Inc). The predecessor company of Protherics Molecular Design Limited was Proteus Molecular Design Limited.

This application forms part of a portfolio of patent applications directed to serine protease inhibitors, some of which belong to Eli Lilly and Company, and some of which belong to Tularik Limited. The history of this portfolio

Serial No. 10/030,187


traces back to a research project on serine protease inhibitors started by Proteus Molecular Design Limited. The undersigned is responsible for handling the applications in this portfolio.

A listing of the co-pending applications and patents in the portfolio is attached.

COMMUNICATION BY TELEPHONE

In the Office Communication, the Examiner has remarked that he is unable to telephone the undersigned. The undersigned can also be contacted by e-mail at martinahay@martin-a-hay.com, and would be pleased to telephone the Examiner in response.

Respectfully submitted,



Hay, Martin Alexander

Agent for Applicants

Registration No. 39,459

Phone: 011 44 1625 500057

e-mail: martinahay@martin-a-hay.com

Martin A. Hay & Co.,  
13 Queen Victoria Street  
Macclesfield  
Cheshire  
SK11 6LP  
UNITED KINGDOM

June 9, 2003

Serial No. 10/030,187

**Co-Pending Lilly and Tularik Applications and Patents**

**Co-pending applications - Assigned to Eli Lilly and Company**

09/926,712 (national stage of WO 00/76971)

09/926,716 (national stage of WO 00/76970 - abandoned)

10/030,188 (national stage of WO 01/96303)

10/030,186 (national stage of WO 01/96304)

10/030,189 (national stage of WO 01/96296)

**4. Co-pending applications and patents - Assigned to Tularik Limited**

US 6262069 and US 6420438 (national stage of WO 99/11657 and continuation)

09/988,082 (continuation-in-part of 09/485,678, WO 99/11658 and of WO 00/77027)

10/148,174 (national stage of WO 01/44226)

10/296,245 (national stage of WO 01/96305)